Publikationen

Bredehöft J., Dolga A.M., Honrath B., Wache S., Mazurek S., Culmsee C., Schoemaker R.G., Gerstberger R., Roth J. und Rummel C.
SK-channel activation alters peripheral metabolic pathways in mice, but not lipopolysaccharide-induced fever or inflammation. J. Inflamm. Res. 15: 509-531, 2022.

Vélez J., Silva L.M.R., Kamena F.,  Daugschies A., Mazurek S., Hermosilla C. und Taubert A.

The oesophagal squamous cell carcinoma cell line COLO-680N fails to support sustained Cryptosporidium parvum proliferation. Pathogens 11: 49, 2022. 

Vélez J., Velasquez Z., Silva L.M.R., Gärtner U., Failing K., Daugschies A., Mazurek S., Hermosilla C. und Taubert A.

Metabolic signatures of Cryptosporidium parvum-infected HCT-8 cells and impact of selected metabolic inhibitors on C. parvum infection under Physioxia and Hyperoxia. Biology 10: 60, 2021.

Khan A., Siddiqui S., Husain S.A., Mazurek S. und Iqbal M.A.

Phytocompounds Targeting Metabolic Reprogramming in Cancer: An Assessment of Role, Mechanisms, Pathways, and Therapeutic Relevance. J Agric. Food Chem. Doi: 10.1021/acs.jafc.1c01173, 2021.

Velásquez Z., López-Osorio S., Mazurek S., Hermosilla C. und Taubert A.

Eimeria bovis Macromeront Formation Induces Glycolytic Responses and Mitochondrial Changes in Primary Host Endothelial Cells. Front. Cell Infect. Microbiol. 11: 703413, 2021.

Vélez J., Silva L.M.R., Gärtner U., Daugschies A., Mazurek S., Hermosilla C. und Taubert A.

First metabolic insights into ex vivo Cryptosporidium parvum infected bovine small intestinal explants studied under physioxic conditions. Biology 10: 963, 2021.

Khatri R., Mazurek S., Petry S.F. und Linn T.

Mesenchymal stem cells promote pancreatic β-cell regeneration through downregulation of FoxO1 pathway. Stem Cell Res. Ther. 11: 497, 2020.

Glenske K., Schäpe K., Wieck A., Failing K., Werner J., Rohnke M., Wenisch S. und Mazurek S.

Effect of long term palmitate treatment on osteogenic differentiation of human mesenchymal stromal cells - Impact of albumin. Bone Reports 13: 100707, 2020.

Zhou E., Conejeros I., Gärtner U., Mazurek S., Hermosilla C. und Taubert, A.

Metabolic requirements of Besnoitia besnoiti tachyzoite-triggered NETosis. Parasitology Res. 119: 545-557, 2020.

Matés J.M., Di Paola F.J., Campos-Sandoval J.A., Mazurek S. und Márquez J.:

Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer. Semin, Cell Dev. Biol. 98: 34-43, 2020.

Kruppke B., Wagner A.S., Rohnke M., Heinemann C., Kreschel C., Gebert A., Wiesmann H.P., Mazurek S., Wenisch S. und Hanke T.

Biomaterial based treatment of osteoclastic/osteoblastic cell imbalance - Gelatin-modified calcium/strontium phosphates. Mater Sci. Eng. C Mater Biol Appl. 104: 109933. doi: 10.1016/j.msec.2019.109933, 2019.

Wagner A.S., Schumacher M., Rohnke M., Glenske K., Gelinsky M., Arnhold S., Mazurek S. und Wenisch S.

Incorporation of silicon into strontium modified calcium phosphate bone cements promotes osteoclastogenesis of human peripheral mononuclear blood cells. Biomed. Mater. 14: 025004, doi: 10.1088/1748-605X/aaf701, 2019.

Prakasam G., Iqbal M.A., Bamezai R.N.K., Mazurek S.
Posttranslational Modifications of Pyruvate Kinase M2: Tweaks that Benefit Cancer. Front. Oncol. 8: 22. doi: 10.3389/fonc.2018.00022, 2018.

Wache S., Helmig S., Walter D., Schneider J. und Mazurek S.
Impact of biopersistent fibrous dusts on glycolysis, glutaminolysis and serine metabolism in A549 cells. Mol. Med. Reports 16: 9233-9241, 2017.

Wagner A., Glenske K., Wolf V., Fietz D., Mazurek S., Hanke T., Moritz A., Arnhold S. und Wenisch S. Osteogenic differentiation capacity of human mesenchymal stromal cells in response to extracellular calcium with special regard to connexin 43. Ann. Anat. 209: 18–24, 2017.

Taubert A., Hermosilla, C. Silva L.M.R., Wieck A., Failing K. und Mazurek S.
Metabolic signatures of Besnoitia besnoiti-infected endothelial host cells and blockage of key metabolic pathways indicate high glycolytic and glutaminolytic needs of the parasite. Parasitol. Res. 115: 2023-2034, 2016.

Iqbal M.A., Gupta V., Gopinath P., Mazurek S. and Bamezai R.N.

Pyruvate kinase M2 and cancer: an updated assessment. FEBS Lett. 588: 2685-2692, 2014.

Gupta V., Wellen K.E., Mazurek S. und Bamezai R.N.K.
Pyruvate Kinase M2: Regulatory Circuits and Potential for Therapeutic Intervention. Curr. Pharm. Des. 20: 2595-2606, 2014.

Gupta V., Gopinath P., Iqbal M.A., Mazurek S., Wellen K.E. und Bamezai R.N.K.
Interplay Between Epigenetics & Cancer Metabolism. Curr. Pharm. Des. 20: 1706-1714, 2014.

Dhar D.K., Olde Damink S.W.M., Brindley J.H., Godfrey A., Chapman M.H., Sandanayake N.S., Andreola F., Mazurek S., Hasan R., Malago M. und Pereira S.P.
Pyruvate kinase M2 is a novel diagnostic marker and predicts tumour progression in human biliary tract cancer. Cancer 119(3): 575-585, 2012.

Mazurek S.
Pyruvate kinase M2: a key enzyme of the tumor metabolome and ist medical relevance. Biomedical Research 23: SI133-141, 2012.

Mazurek S.
Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol. 43: 969-980, 2011.

Kumar Y., Yang S., Mazurek S., Failing K., Winslet M., Fuller B. und Davidson B.R.
In-vivo factors influencing tumor M2-pyruvate kinase level in human pancreatic cancer cell lines. Tumor Biology 31: 69-77, 2010.

Mazurek S.
M2-PK-Test zur Früherkennung von kolorektalen Karzinomen. Erfahrungsheilkunde 59: 200-205, 2010.

Spoden G.A., Rostek U., Mazurek S. und Zwerschke W.
Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size, apoptotic cell death and cellular redox potential dependent on glucose supply. Exp. Cell Res. 315: 2765-2774, 2009.

Mazurek S.
80 Jahre nach der Warburg-Hypothese: Über die Bedeutung des Stoffwechsels für das Tumorwachstum. TIG – Zeitschrift des Vereins der Freunde und Förderer der Veterinärmedizin an der Justus-Liebig-Universität Gießen e.V. 2: 43-44, 2009.

Unterluggauer H., Mazurek S., Lener E., Hütter E., Eigenbrodt E., Zwerschke W. und Jansen-Dürr P.
Premature senescence of human endothelial cells induced by inhibition of glutaminase. Biogerontology 9: 247-259, 2008.

Vizan P., Mazurek S. und Cascante M.
Robust metabolic adaption underlying tumor progression. Metabolomics 4: 1-12, 2008.

Spoden G.A., Mazurek S., Morandell D., Bacher N., Ausserlechner M.J., Jansen-Dürr P., Eigenbrodt E. und Zwerschke W.
Isotype specific inhibitors of the metabolic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation. Int. J. Cancer 123: 312-321, 2008.

Mazurek S.
Das Tumor-Metabolom – eine Quelle von Messgrößen zur frühzeitigen Diagnose von Tumoren. In: Tumormarker in der Gastroenterologie (Editor: P.D. Hardt), Uni-Med-Verlag, Bremen: 57-67, 2008.

Mazurek S.
Pyruvate kinase type M2: A key regulator within the tumour metabolome and a tool for metabolic profiling of tumours. Ernst Schering Foundation Symposium Proceedings 07.4 “Oncogenes meet metabolism – from deregulated genes to a broader understanding of tumour physiology” (Editoren: G. Kroemer, D. Mumberg, H. Keun, B. Riefke, Th. Steger-Hartmann, K. Petersen), Springer Verlag, Berlin-Heidelberg-New York: 4: 99-124, 2008.

Mazurek S.
Tumour cell energetic metabolome. In: Wiley Encyclopedia of Chemical Biology. (Editor: T.P. Begley), John Wiley and Sons Inc. 4: 624-635, 2008.

Mazurek S., Hugo F. und Zwerschke W.
PKM2. Atlas of Genetics and Cytogenetics in Oncology and Haematology 2008:
URL: http://atlasgeneticsoncology.org/Genes/PKM2ID41728ch15q22.html

Mazurek S.
Pyruvate kinase isoenzyme type M2: Its role in tumor metabolism, tumor therapy and tumor diagnosis. Auf Einladung in: Scirus Topic Pages 2008:
http://topics.scirus.com/Pyruvate_kinase_isoenzyme_type_M2_its_role_in_tumor_metabolism_tumor_therapy_and_tumor_diagnosis.html

Mazurek S., Drexler H.C.A., Troppmair J., Eigenbrodt E. und Rapp U.R.
Regulation of pyruvate kinase type M2 by A-Raf: a possible glycolytic stop or go mechanism. Anticancer Res. 27: 3963-3972, 2007.

Nafz J., De-Castro Arce J., Fleig V., Patzelt A., Mazurek S. und Rösl F.
Interference with energy metabolism by 5-aminoimidazole-4-carboxamide -1-beta-D-rubofuranoside induces HPV suppression in cervical carcinoma cells and apoptosis in the absence of LKB1. Biochem. J. 403: 501-510, 2007.

Mazurek S.
Tumour cell energetic metabolome. In: Molecular System Bioenergetics – Energy for Life (Editor: V. Saks), Wiley-VCH, Weinheim: 521-540, 2007.

Müllner S., Stark H., Niskanen P., Eigenbrodt E., Mazurek S. und Fasold H.
From target to lead synthesis. In: Proteomics in Drug Research (Editoren: M. Hamacher, K. Marcus, K. Stühler, A. van Hall, B. Warscheid, H.E. Meyer), Wiley-VCH, Weinheim, Vol. 26: 187-207, 2006.

Mazurek S., Boschek C.B., Hugo F. und Eigenbrodt E.
Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol: 15: 300-308, 2005.

Engel M., Mazurek S., Eigenbrodt E. und Welter C.
Phosphoglycerate mutase-derived polypeptide inhibits glycolytic flux and induces cell growth arrest in tumor cell lines. J. Biol. Chem. 279: 35803-35812, 2004.

Hardt P.D., Mazurek S., Toepler M., Schlierbach P., Bretzel R.G., Eigenbrodt E. und Klör H.U.
Faecal tumour M2 pyruvate kinase: A new, sensitive screening tool for colorectal cancer. Br. J. Cancer 91: 980-984, 2004.

Hardt P.D., Mazurek S., Klör H.U. und Eigenbrodt E.
Neuer Stuhltest „Tumor M2-PK“ zum Screening von Darmkrebs. Von der Grundlagenforschung zur klinischen Anwendung. Spiegel der Forschung (Wissenschaftsmagazin der Justus-Liebig-Universität Gießen) 1/2: 14-19, 2004.

Zwerschke W., Mazurek S., Stöckl P., Hütter E., Eigenbrodt E. und Jansen-Dürr P.
Metabolic analysis of senescent human fibroblasts reveals a role for AMP in cellular senescence. Biochem. J. 276: 403-411, 2003.

Garcia-Gonzalo F.R., Cruz C., Muñoz P., Mazurek S., Eigenbrodt E., Ventura F., Bartrons R. und Rosa J.L.
Interaction between HERC1 and M2-type pyruvate kinase. FEBS Lett. 539: 78-84, 2003.

Mazurek S. und Eigenbrodt E.
The tumor metabolome. Anticancer Res. 23: 1149-1154, 2003.

Lüftner D., Mazurek S., Henschke P., Mesterharm J., Schildhauer S., Geppert R., Wernecke K.D. und Possinger K.
Plasma levels of HER-2/neu, Tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer. Anticancer Res. 23: 991-998, 2003.

Le Mellay V., Houben R., Troppmair J., Hagemann C., Mazurek S., Frey U., Beigel J., Weber C.M., Benz R., Eigenbrodt E. und Rapp U.
Regulation of glycolysis by Raf protein serine/threonine kinases. Adv. Enzyme Regul. 42: 317-332, 2002.

Mazurek S., Grimm H., Boschek C.B., Vaupel P. und Eigenbrodt E.
Pyruvate kinase type M2: A crossroad in the tumor metabolome. Brit. J. Nutr. 87: S23-S29, 2002.

Mazurek S., Lüftner D., Wechsel H.W., Schneider J. und Eigenbrodt E.
Tumor M2-PK: a marker of the tumor metabolome. In: Tumor Markers-Physiology, Pathobiology, Technology, and Clinical Applications. (Editoren: E.P. Diamandis, H.A. Fritsche, H. Lilja, D.W. Chan und M.K. Schwartz), AACC Press Washington: 471-475, 2002.

Mazurek S., Zwerschke W., Jansen-Dürr P. und Eigenbrodt E.
Metabolic cooperation between different oncogenes during cell transformation: Interaction between activated ras and HPV-16 E7. Oncogene 20: 6891-6898, 2001.

Mazurek S., Zwerschke W., Jansen-Dürr P. und Eigenbrodt E.
Effect of the human papillomavirus  HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: Role of pyruvate kinase type M2 and the glycolytic enzyme complex. Biochem. J. 356: 247-256, 2001.

Mazurek S., Grimm H., Oehmke M., Weisse G., Teigelkamp S. und Eigenbrodt E.
Tumor M2-PK and glutaminolytic enzymes in the metabolic shift of tumor cells. Anticancer Res. 20: 5151-5154, 2000.

Lücker E., Mazurek S. und Eigenbrodt E.
Apoptose und Eutergesundheit. Tierärztliche Praxis 28: 182-188, 2000.

Mazurek S., Weisse G., Wüst G., Schäfer-Schwebel A., Eigenbrodt E. und Friis R.R.
Energy metabolism in the involuting mammary gland. In vivo 13: 467-478, 1999.

Mazurek S., Eigenbrodt E., Failing K. und Steinberg P.
Alterations in the glycolytic and glutaminolytic pathways after malignant transformation of rat liver oval cells. J. Cell. Physiol. 181: 136-146, 1999.

Zwerschke W., Mazurek S., Massimi P., Banks L., Eigenbrodt E. und Jansen-Dürr P.
Modulation of pyruvate kinase type M2 by the human papillomavirus type 16 E7 oncoprotein. Proc. Natl. Acad. Sci. USA 96: 1291-1296, 1999.

Lücker E., Mazurek S. und Eigenbrodt E.
Zum Nachweis des Apoptose-Markers Poly-(ADP-Ribose)Polymerase in Milchdrüse und Milch: Ein neuer Ansatzpunkt zur Charakterisierung der Eutergesundheit. Verlag der Deutschen Veterinärmedizinischen Gesellschaft, Gießen: 463-468, 1999.

Bitsch N., Mazurek S., Körner W. und Brunn H.
Application of the E-screen to assess the estrogenic activity of pyrethroids. Tagungsband zum 7. Symposium „Vitamine und Zusatzstoffe in der Ernährung von Mensch und Tier“, 531-534, 1999.

Eigenbrodt E., Mazurek S. und Friis R.
Double role of pyruvate kinase type M2 in the regulation of phosphometabolite pools. In: Cell Growth and Oncogenesis. (Editoren: P. Bannasch, D. Kanduc, S. Papa und J.M. Tager), Birkhäuser Verlag, Basel: 15-30, 1998.

Mazurek S., Grimm H., Wilker S., Leib S. und Eigenbrodt E.
Metabolic characteristics of different malignant cancer cell lines. Anticancer Res. 18: 3275-3282, 1998.

Eigenbrodt E., Kallinowski F., Ott M., Mazurek S. und Vaupel P.
Pyruvate kinase and the interaction of amino acid and carbohydrate metabolism in solid tumors. Anticancer Res. 18: 3267-3274, 1998.

Mazurek S., Michel A. und Eigenbrodt E.
Effect of extracellular AMP on cell proliferation and metabolism of breast cancer cell lines with high and low glycolytic rates. J. Biol. Chem. 272: 4941-4952, 1997.

Eigenbrodt E., Basenau D., Holthusen S., Mazurek S. und Fischer G.
Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas. Anticancer Res. 17: 3153-3156, 1997.

Mazurek S., Boschek C.B. und Eigenbrodt E.
The role of phosphometabolites in cell proliferation, energy metabolism, and tumor formation. J. Bioenerg. Biomembr. 29: 315-330, 1997.

Mazurek S., Hugo H., Failing K. und Eigenbrodt E.
Studies on associations of glycolytic and glutaminolytic enzymes in MCF-7 cells. Role of p36. J. Cell. Physiol. 167: 238-250, 1996.

Eigenbrodt E., Gerbracht U., Mazurek S., Presek P. und Friis R.
Carbohydrate metabolism and neoplasia: New perspectives for diagnosis and therapy. In: Biochemical and Molecular Aspects of Selected Cancers. (Editoren: T.G. Pretlow und T.P. Pretlow), Academic Press INC. San Diego 2: 311-385, 1994.

Scheefers-Borchel U., Scheefers H., Michel A., Will H., Fischer G., Basenau D., Dahlmann N., Laumen R., Mazurek S. und Eigenbrodt E.
Quantitative determination (ELISA) of pyruvate kinase type M2 (A new tumor marker). In: Current Tumor Diagnosis: Applications, Clinical Relevance, Research - Trends. (Editor: R. Klapdor), W. Zuckschwerdt Verlag, München: 365-368, 1994.

Eigenbrodt E. und Mazurek S.
Möglichkeiten und Grenzen von Ergänzungs- und Ersatzmethoden aus der Sicht der Forschung und angewandten Diagnostik. In: Schriftreihe der Akademie für Tiergesundheit 4: 225-230, 1994.

Brinck U., Eigenbrodt E., Oehmke M., Mazurek S. und Fischer G.
L- and M2-PK expression in renal cell carcinomas and their metastases. Virchows Archiv. B 424: 177-185, 1994.

Mazurek S., Scheefers-Borchel U., Scheefers H., Michel A., Basenau D., Fischer G., Dahlmann N., Laumen R. und Eigenbrodt E.
Die Bedeutung der Pyruvatkinase in der Onkologie. Notabene medici 3: 97-104, 1993.

Hugo F., Mazurek S., Zander U. und Eigenbrodt E.
In vitro effect of extracellular AMP on MCF-7 breast cancer cells: Inhibition of glycolysis and cell proliferation. J. Cell. Physiol. 153: 539-549, 1992.